Weijun Fu
YOU?
Author Swipe
View article: Clinical and genomic features of macrofocal multiple myeloma: a distinct profile
Clinical and genomic features of macrofocal multiple myeloma: a distinct profile Open
Not available.
View article: Krüppel-like factor 5 transcription factor is a positive regulator of NRG-1 in human coronary artery smooth muscle cells
Krüppel-like factor 5 transcription factor is a positive regulator of NRG-1 in human coronary artery smooth muscle cells Open
View article: Development and validation of a prognostic staging system for primary plasma cell leukemia
Development and validation of a prognostic staging system for primary plasma cell leukemia Open
View article: Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study
Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study Open
View article: Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC‐1
Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC‐1 Open
Introduction Teclistamab, the first approved B‐cell maturation antigen‐directed bispecific antibody for treatment of triple‐class exposed relapsed/refractory multiple myeloma, demonstrated deep, durable responses with a manageable safety p…
View article: Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study
Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study Open
View article: Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis
Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis Open
Our results indicate that MM patients with RI could benefit from a daratumumab-added regimen regardless of MM status. Additional high-quality RCTs are still warranted to confirm our findings.
View article: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study Open
View article: Safety and Reliability of Urological Telesurgery: A Multi-Center, Single-Blind, Exploratory, Randomized Control Trial
Safety and Reliability of Urological Telesurgery: A Multi-Center, Single-Blind, Exploratory, Randomized Control Trial Open
View article: Multi-omics investigation of the resistance mechanisms of pomalidomide in multiple myeloma
Multi-omics investigation of the resistance mechanisms of pomalidomide in multiple myeloma Open
Background Despite significant therapeutic advances over the last decade, multiple myeloma remains an incurable disease. Pomalidomide is the third Immunomodulatory drug that is commonly used to treat patients with relapsed/refractory multi…
View article: P874: LONG-TERM REMISSION AND SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AFTER TREATMENT OF LCAR-B38M CAR-T – AT LEAST 5-YEAR FOLLOW-UP IN LEGEND-2
P874: LONG-TERM REMISSION AND SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AFTER TREATMENT OF LCAR-B38M CAR-T – AT LEAST 5-YEAR FOLLOW-UP IN LEGEND-2 Open
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: LCAR-B38M CAR-T cells express a structurally differentiated chimeric antigen receptor (CAR) construct containing a 4-1BB costimulatory domain and 2 BCMA-targeting …
View article: PB2269: PI3KΔ INHIBITOR LINPERLISIB FOR ELDERLY PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL
PB2269: PI3KΔ INHIBITOR LINPERLISIB FOR ELDERLY PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL Open
Topic: 18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical Background: Elderly patients have limited therapy strategies due to physical condition and tolerability. Although PI3K inhibitors have been conditionally approved for some…
View article: P869: UPDATED RESULTS OF A PHASE I, OPEN-LABEL STUDY OF BCMA/CD19 DUAL-TARGETING FASTCAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
P869: UPDATED RESULTS OF A PHASE I, OPEN-LABEL STUDY OF BCMA/CD19 DUAL-TARGETING FASTCAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) Open
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: GC012F is a B cell maturation antigen (BCMA) and CD19 dual-targeting chimeric antigen receptor (CAR)-T cell developed on the novel FasTCAR-T platform enabling 22-3…
View article: PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL
PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL Open
Topic: 18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical Background: Linperlisib (YY-20394) is an oral PI3Kδ-selective inhibitor. In a multicenter phase 2 trial (NCT04370405), the efficacy and safety of linperlisib as third- or …
View article: Multi-omics investigation of the resistance mechanisms of Pomalidomide in Multiple Myeloma
Multi-omics investigation of the resistance mechanisms of Pomalidomide in Multiple Myeloma Open
Background Despite significant therapeutic advances over the last decade, Multiple myeloma remains an incurable disease. Pomalidomide is a second-generation Immunomodulatory drug that is commonly used to treat patients with relapsed/refrac…
View article: [15q26 deletion syndrome with pure red cell aplastic anemia: a case report].
[15q26 deletion syndrome with pure red cell aplastic anemia: a case report]. Open
View article: Effects of Reduced Fertilization Combinedwith Titanium Gypsum on Soil Arsenicand Cadmium and Water Spinach(<i>Ipomoea aquatica</i> Forsk) Growth
Effects of Reduced Fertilization Combinedwith Titanium Gypsum on Soil Arsenicand Cadmium and Water Spinach(<i>Ipomoea aquatica</i> Forsk) Growth Open
Many industrial by-products have been used to fix heavy metals in contaminated soil.In this study, three amendments (titanium gypsum (TG) and two simulated titanium gypsum (STG1; STG2) were used to immobilize arsenic (As) and cadmium (Cd) …
View article: Supplementary Figure S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Supplementary Figure S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial Open
Comparison of the concentrations of serum markers measured in patients with and without a response to linperlisib
View article: Supplementary Table S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Supplementary Table S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial Open
List of participating hospitals for the clinical trial NCT04370405
View article: Supplementary Figure S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Supplementary Figure S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial Open
Comparison of the concentrations of serum markers measured in patients with and without a response to linperlisib
View article: Supplementary Table S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Supplementary Table S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial Open
Detailed inclusion and exclusion criteria for the clinical trial (NCT04370405)
View article: Supplementary Figure S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Supplementary Figure S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial Open
Serum cytokine concentrations before and during treatment
View article: Data from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Data from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial Open
Purpose:To investigate the efficacy and safety of the novel orally active PI3Kδ inhibitor in relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least two prior systemic treatments.Patients and Methods:His…
View article: Supplementary Table S4 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Supplementary Table S4 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial Open
Investigator-assessed response outcomes (FAS)
View article: Supplementary Table S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Supplementary Table S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial Open
List of participating hospitals for the clinical trial NCT04370405
View article: Supplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Supplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial Open
Subgroup analysis of (A) ORR, (B) DOR and (C) PFS confirmed by investigator
View article: Supplementary Figure S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Supplementary Figure S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial Open
Serum cytokine concentrations before and during treatment
View article: Supplementary Table S4 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Supplementary Table S4 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial Open
Investigator-assessed response outcomes (FAS)
View article: Supplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Supplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial Open
Subgroup analysis of (A) ORR, (B) DOR and (C) PFS confirmed by investigator
View article: Supplementary Table S6 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Supplementary Table S6 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial Open
Comparison of PI3K inhibitor toxicities and their efficacies for relapsed and/or refractory indolent lymphoma treatments